Globeflex Capital L P Purchases New Position in Guardian Pharmacy Services, Inc. $GRDN

Globeflex Capital L P purchased a new stake in Guardian Pharmacy Services, Inc. (NYSE:GRDN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 44,354 shares of the company’s stock, valued at approximately $1,335,000.

Several other institutional investors have also bought and sold shares of GRDN. Ameritas Investment Partners Inc. boosted its stake in Guardian Pharmacy Services by 26.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock valued at $43,000 after buying an additional 345 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Guardian Pharmacy Services in the 2nd quarter valued at $43,000. State of Wyoming acquired a new stake in Guardian Pharmacy Services in the 2nd quarter valued at $58,000. Strs Ohio acquired a new position in Guardian Pharmacy Services in the fourth quarter worth $75,000. Finally, Clearstead Advisors LLC boosted its stake in Guardian Pharmacy Services by 196.3% in the fourth quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after purchasing an additional 1,741 shares in the last quarter.

Guardian Pharmacy Services Stock Up 4.3%

GRDN stock opened at $40.81 on Friday. The company has a market cap of $2.03 billion, a P/E ratio of 49.16, a PEG ratio of 2.57 and a beta of 0.08. Guardian Pharmacy Services, Inc. has a twelve month low of $19.17 and a twelve month high of $41.36. The business has a fifty day moving average of $37.57 and a 200-day moving average of $33.54.

Guardian Pharmacy Services (NYSE:GRDN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05. Guardian Pharmacy Services had a return on equity of 30.72% and a net margin of 3.64%.The business had revenue of $336.60 million during the quarter, compared to the consensus estimate of $329.89 million. During the same quarter in the prior year, the company posted $0.22 earnings per share. The firm’s revenue was up 2.2% on a year-over-year basis. As a group, equities research analysts anticipate that Guardian Pharmacy Services, Inc. will post 1.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on GRDN. Zacks Research lowered Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Bank of America began coverage on Guardian Pharmacy Services in a research note on Monday, April 27th. They issued a “buy” rating and a $42.00 price objective on the stock. Wall Street Zen lowered Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group began coverage on Guardian Pharmacy Services in a research note on Monday, March 30th. They issued a “buy” rating and a $44.00 price objective on the stock. Finally, Raymond James Financial reissued an “outperform” rating and issued a $40.00 price objective on shares of Guardian Pharmacy Services in a research note on Thursday, March 12th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $41.33.

Insider Buying and Selling

In other Guardian Pharmacy Services news, insider David K. Morris sold 187,855 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $5,575,536.40. Following the completion of the sale, the insider directly owned 254,472 shares in the company, valued at $7,552,728.96. This represents a 42.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kendall Forbes sold 346,672 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $10,289,224.96. Following the completion of the sale, the insider owned 453,256 shares of the company’s stock, valued at $13,452,638.08. This trade represents a 43.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 9,726,405 shares of company stock valued at $288,679,700. 32.96% of the stock is owned by company insiders.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.